BACKGROUND: Since there are no certified therapeutics to treat COVID-19 patients, drug repurposing became important. With lack of time to test individual pharmacogenomics markers, population pharmacogenomics could be helpful in predicting a higher risk of developing adverse reactions and treatment failure in COVID-19 patients. Aim of our study was to identify pharmacogenes and pharmacogenomics markers associated with drugs recommended for COVID-19 treatment, chloroquine/hydroxychloroquine, azithromycin, lopinavir and ritonavir, in population of Serbia and other world populations. METHODS: Genotype information of 143 individuals of Serbian origin was extracted from database previously obtained using TruSight One Gene Panel (Illumina). Genotype data of individuals from different world populations were extracted from the 1000 Genome Project. Fisher's exact test was used for comparison of allele frequencies. RESULTS: We have identified 11 potential pharmacogenomics markers in 7 pharmacogenes relevant for COVID-19 treatment. Based on high alternative allele frequencies in population and the functional effect of the variants, ABCB1 rs1045642 and rs2032582 could be relevant for reduced clearance of azithromycin, lopinavir and ritonavir drugs and UGT1A7 rs17868323 for hyperbilirubinemia in ritonavir treated COVID-19 patients in Serbian population. SLCO1B1 rs4149056 is a potential marker of lopinavir response, especially in Italian population. Our results confirmed that pharmacogenomics profile of African population is different from the rest of the world. CONCLUSIONS: Considering population specific pharmacogenomics landscape, preemptive testing for pharmacogenes relevant for drugs used in COVID-19 treatment could contribute to better understanding of the inconsistency in therapy response and could be applied to improve the outcome of the COVID-19 patients.
BACKGROUND: Since there are no certified therapeutics to treat COVID-19 patients, drug repurposing became important. With lack of time to test individual pharmacogenomics markers, population pharmacogenomics could be helpful in predicting a higher risk of developing adverse reactions and treatment failure in COVID-19 patients. Aim of our study was to identify pharmacogenes and pharmacogenomics markers associated with drugs recommended for COVID-19 treatment, chloroquine/hydroxychloroquine, azithromycin, lopinavir and ritonavir, in population of Serbia and other world populations. METHODS: Genotype information of 143 individuals of Serbian origin was extracted from database previously obtained using TruSight One Gene Panel (Illumina). Genotype data of individuals from different world populations were extracted from the 1000 Genome Project. Fisher's exact test was used for comparison of allele frequencies. RESULTS: We have identified 11 potential pharmacogenomics markers in 7 pharmacogenes relevant for COVID-19 treatment. Based on high alternative allele frequencies in population and the functional effect of the variants, ABCB1 rs1045642 and rs2032582 could be relevant for reduced clearance of azithromycin, lopinavir and ritonavir drugs and UGT1A7 rs17868323 for hyperbilirubinemia in ritonavir treated COVID-19 patients in Serbian population. SLCO1B1 rs4149056 is a potential marker of lopinavir response, especially in Italian population. Our results confirmed that pharmacogenomics profile of African population is different from the rest of the world. CONCLUSIONS: Considering population specific pharmacogenomics landscape, preemptive testing for pharmacogenes relevant for drugs used in COVID-19 treatment could contribute to better understanding of the inconsistency in therapy response and could be applied to improve the outcome of the COVID-19 patients.
Entities:
Keywords:
COVID-19; azithromycin; chloroquine/hydroxychloroquine; lopinavir; pharmacogenomics markers; population pharmacogenomics; ritonavir
Authors: Andrew D Yates; Premanand Achuthan; Wasiu Akanni; James Allen; Jamie Allen; Jorge Alvarez-Jarreta; M Ridwan Amode; Irina M Armean; Andrey G Azov; Ruth Bennett; Jyothish Bhai; Konstantinos Billis; Sanjay Boddu; José Carlos Marugán; Carla Cummins; Claire Davidson; Kamalkumar Dodiya; Reham Fatima; Astrid Gall; Carlos Garcia Giron; Laurent Gil; Tiago Grego; Leanne Haggerty; Erin Haskell; Thibaut Hourlier; Osagie G Izuogu; Sophie H Janacek; Thomas Juettemann; Mike Kay; Ilias Lavidas; Tuan Le; Diana Lemos; Jose Gonzalez Martinez; Thomas Maurel; Mark McDowall; Aoife McMahon; Shamika Mohanan; Benjamin Moore; Michael Nuhn; Denye N Oheh; Anne Parker; Andrew Parton; Mateus Patricio; Manoj Pandian Sakthivel; Ahamed Imran Abdul Salam; Bianca M Schmitt; Helen Schuilenburg; Dan Sheppard; Mira Sycheva; Marek Szuba; Kieron Taylor; Anja Thormann; Glen Threadgold; Alessandro Vullo; Brandon Walts; Andrea Winterbottom; Amonida Zadissa; Marc Chakiachvili; Bethany Flint; Adam Frankish; Sarah E Hunt; Garth IIsley; Myrto Kostadima; Nick Langridge; Jane E Loveland; Fergal J Martin; Joannella Morales; Jonathan M Mudge; Matthieu Muffato; Emily Perry; Magali Ruffier; Stephen J Trevanion; Fiona Cunningham; Kevin L Howe; Daniel R Zerbino; Paul Flicek Journal: Nucleic Acids Res Date: 2020-01-08 Impact factor: 16.971
Authors: Elisa Danese; Martina Montagnana; Gian Luca Salvagno; Matteo Gelati; Denise Peserico; Laura Pighi; Simone de Nitto; Brandon M Henry; Stefano Porru; Giuseppe Lippi Journal: J Med Biochem Date: 2021-09-03 Impact factor: 3.402
Authors: Gian Luca Salvagno; Brandon M Henry; Giovanni di Piazza; Laura Pighi; Simone de Nitto; Damiano Bragantini; Gian Luca Gianfilippi; Giuseppe Lippi Journal: J Med Biochem Date: 2021-09-03 Impact factor: 3.402
Authors: Theodosia Charitou; Panagiota I Kontou; Ioannis A Tamposis; Georgios A Pavlopoulos; Georgia G Braliou; Pantelis G Bagos Journal: Pharmacogenomics J Date: 2022-09-28 Impact factor: 3.245